MapLight Therapeutics debuts on Nasdaq at $19, above $17 IPO price
PositiveFinancial Markets

MapLight Therapeutics made a successful debut on the Nasdaq, launching its shares at $19, which is above the initial public offering price of $17. This positive start reflects strong investor interest and confidence in the company's potential in the biotech sector, marking a significant milestone for MapLight as it seeks to advance its innovative therapies.
— Curated by the World Pulse Now AI Editorial System







